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1. Introduction 
ABSTRACT 
Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver condition 
worldwide, and is projected to become the leading cause for liver transplantation in the 
United States as early as 2020. The mainstay of treatment remains lifestyle modification with 
diet and exercise recommendations, as although some pharmacological treatments such as 
glitazones and Vitamin E have shown benefit, there are concerns regarding long term safety. 
The evidence base for dietary interventions in NAFLD such as the Mediterranean diet, omega-3 
polyunsaturated fatty acids and coffee is mainly derived from observational data with 
questionable validity. Where trials exist, they have shown benefit for surrogate outcomes such 
as hepatic steatosis and insulin resistance, but no trials have been conducted with salient 
clinical outcomes such as reduction in progression to chronic liver disease. Benefit in 
surrogate outcomes has also been seen for aerobic, anaerobic and combined modality exercise 
but it remains unclear if one type is superior. Furthermore, a reduction in sedentary time 
appears equally important. To provide a sound evidence base for lifestyle recommendations to 
people with NAFLD, longer duration trials of standardized dietary or exercise interventions, 
and testing various doses , types and with liver related outcomes, are essential. 
© 2015 Published by Elsevier Inc. 
Nonalcoholic fatty liver disease (NAFLD) is considered the hepatic 
manifestation of the metabolic syndrome as it is tightly linked 
with the global obesity epidemic [1]; indeed, recent data suggest 
that NAFLD may even precede the development of the metabolic 
syndrome and type 2 diabetes [2]. NAFLD covers a spectrum of 
liver histology from bland steatosis to hepatocyte ballooning, 
inflammation (known as nonalcoholic steatohepatitis, NASH), 
fibrosis and cirrhosis, with an increased risk of hepatocellular 
carcinoma. The prevalence ofNAFLD is approximately 30% in the 
United States and Europe (3---5]. with a similar prevalence 48 
documented in Asian countries [6] . The prevalence of NASH is 49 
estimated at 4% [4] and is likely to eclipse other forms of liver so 
disease as the primary indication for liver transplantation in the 51 
United States in the next decade [7] . Pharmacological agents for 52 
NASH show benefit (8,9]. but there are concerns regarding long 53 
term safety, and novel insulin sensitizers are not proven for 54 
mainstream use [10], thus lifestyle modification with diet and 55 
exercise remains first line therapy (11,12]. This review examines 56 
the evidence base for dietary and exercise recommendations for 57 
people with NAFLD and/or NASH, focusing on trial based data 58 
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; CBT, cognitive behavioral therapy; 
HOMA-IR, homeostasis model assessment of insulin resistance; HCC, hepatocellular carcinoma; IHTG, intrahepatic triglycerides; MR-S, 
magnetic resonance spectroscopy; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; PUFA, polyunsaturated 
fatty acids. 
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where available due to the considerable biases that affect validity 
of observational studies and diet. 
2. Literature Search 
A systematic literature search was undertaken to inform this 
review. The initial literature search was PERFORMED in Medline 
via the Ovid platform, and the MeSH terms "fatty liver" and text 
words describing fatty liver (NAFLD, fatty liver, NASH) were 
combined with MeSH terms and text words for dietary compo-
nents and exercise. Searches were then filtered for reviews and 
meta-analyses using the review.pt or meta-analysis.pt filters. In 
addition, the Cochrane Database of Systematic Reviews was 
searched to obtain systematic reviews of dietary or exercise 
interventions for NAFLD. Reference lists of retrieved articles 
were perused to obtain additional references. Although a 
number of well conducted reviews have recently been published 
[13-15). this review focuses primarily on lifestyle ir.terventions 
for which there is a high level of evidence, from either trials or 
systematic reviews thereof. Where the evidence base is low, 
consisting of observational or animal studies only, this is 
highlighted to the reader. 
3. Dietary Interventions for NAFLD: The 
Mediterranean diet, Macronutrients 
and Micronutrients 
3.1. Mediterranean Diet 
In recent years, there has been increasing interest in the 
Mediterranean diet as an alternative to low fat and calorie-
restricted diets because it may offer important benefits for 
those with dyslipidemia and the metabolic syndrome. The 
Mediterranean diet incorporates the traditional food of people 
living in the Mediterranean basin, typified by abundant cereals, 
vegetables and legumes. An important point of difference 
between this and typical Western diets is the profile of fats -
the Mediterranean diet contains predominantly monounsatu-
rated fats from olive oil with a greater ratio of omega-3 
polyunsaturated fatty acids (PUF As) to omega-6 PUF As, whereas 
the reverse is true of Western diets. 
Data from randomized trials of the Mediterranean diet have 
shown benefits in people with type 2 diabetes. In comparison 
with a person's usual diet, a 12 week trial of Mediterranean diet 
resulted in lower HbAlC and plasma levels of saturated and trans 
fatty acids in type 2 diabetics, and did not result in weight gain 
(16]. Trial based evidence also suggests a reduction in insulin 
resistance and inflammatory markers in those with metabolic 
syndrome (17] without associated weight gain (17,18]. More 
recent trial data examining this diet for those at high risk of 
cardiovascular events similarly indicate that a Mediterranean 
diet supplemented with additional olive oil or nuts, in 
comparison with a traditional low fat diet, resulted in a lower 
incidence of major cardiovascular events at 5 years [19] . Preven-
tion of cardiovascular events has also been examined in a 
Cochrane systematic review of 11 trials, which concluded that 
the Mediterranean diet may modulate important cardiovascular 
risk factors (such as lower cholesterol and low-density 
lipoprotein), however meta-analysis was precluded by the vast 114 
heterogeneity of the dietary interventions studied [20]; similar 115 
conclusions have been drawn by non-Cochrane systematic JIG 
reviews (21]. Although it is likely that these data can be directly 117 
extrapolated to people with NAFLD and metabolic syndrome, 118 
there are no randomized trials examining the Mediterranean 119 
diet's effect on clinically important liver related outcomes. A 120 
small crossover trial (n = 12) in patients with biopsy proven 121 
NAFLD of a Mediterranean diet for 6 weeks with crossover to 122 
standard diet at 6 weeks, demonstrated reduced insulin resis- 123 
tance and hepatic steatosis, independent of weight loss (22]. 124 
Specific criticisms of the Mediterranean diet include its higher 125 
cost and a low dairy intake, although as the main dairy is cheese 126 
and yogurt, this may have advantages for lactose intolerant 121 
people. Ideally, long-term trials with liverrelated outcomes as the 128 
primary endpoint would help to inform whether this diet should 129 
be recommended to patients with NAFLD, although such studies 130 
are difficult and expensive to conduct. 
3.2. Macronutrients: Omega-3 vs . Omega-6 
Polyunsaturated Fatty Acids 
131 
132 
133 
The optimal form of dietary fat that should be recommended 134 
to patients with NAFLD has been of intense interest over the 135 
last two decades, in particular the role of polyunsaturated 130 
fatty acids (PUFAs) and the ratio of omega -3 to omega-6. 137 
Polyunsaturated fatty acids include "essential" fatty acids 138 
such as omega-3 and omega-6, so called because they cannot 139 
be synthesized in humans and must be obtained from diet, 140 
and the non-essential fatty acids such as omega-7 and 14 1 
omega-9 fatty acids. Omega-6 fatty acids are derived from 142 
seed oils such as canola and cottonseed, and are metabolized 143 
to a group of compounds known as the eicosanoids (such as 144 
thromboxanes, prostacyclins and leukotrienes) that are in- 145 
volved in inflammatory and thrombotic processes (23]. 14G 
Omega-3 PUFA has been considered beneficial for health on 147 
the basis of promising observational data and has been 148 
enthusiastically studied in diverse conditions such as macular 149 
degeneration, autism, dementia, intermittent claudication, 150 
Crohn's disease, cystic fibrosis, and type 2 diabetes without 151 
evidence of benefit for the primary outcomes studied (24-31). 152 
Relevant to cardiovascular disease in particular, a Cochrane 153 
review of omega-3 PUFA supplementation for primary prophy- 154 
!axis in type 2 diabetics with cardiovascular risk factors showed 155 
improved dyslipidemia without change in glycemic control, J5G 
and mortality or cardiovascular endpoints were not studied 157 
(32]. Further to this , a large trial of omega-3 supplementation as 158 
primary prophylaxis was undertaken in more than 12,000 159 
people, prompted by a previous study showing benefit for 100 
omega-3 use as secondary prophylaxis (33]. After 5 years JG! 
follow-up, this trial concluded that there was no significant 162 
reduction in cardiovascular endpoints, although no serious IG3 
adverse effects were noted (34]. While these data imply that IG4 
omega-3 PUFA may be preferable to other forms, omega-6 PUFA JG5 
may themselves be preferable to saturated fat, as a randomized 166 
trial of supplementation in 61 obese people with omega-6 PUFA 167 
versus saturated fat indicated lower hepatic steatosis, serum 168 
insulin and inflammatory markers in the omega-6 group (35). 169 
With respect to NAFLD in particular, a randomized, placebo 110 
controlled trial in 60 pediatric patients with ultrasound 111 
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diagnosed NAFLD with supplementation of omega-3 PUFA 
(500 mg of docosahexaenoic acid) resulted in reduced liver fat 
and triglycerides and improved insulin sensitivity without 
weight gain [36]. although a similar trial in adults for 18 months 
did not show any improvement on intention to treat analyses 
(37] . However, individual studies may be underpowered, and a 
meta-analysis of omega-3 PUFA supplementation in NAFLD 
suggested an improvement in liver fat, albeit that small, 
although substantial heterogeneity was found [38]; this ques-
tion is to be further addressed in a pending Cochrane review. 
There are few data on hard endpoints such as histology. A 
recently published trial of a synthetic omega-3 PUFA, ethyl-
eicosapentaenoic acid, in 243 patients with histological im-
provement as the primary endpoint did not show an improve-
ment, although surrogate outcomes such as triglycerides 
improved in the intervention group (39). Currently, there is a 
lack of evidence to justify routine recommendation of omega-3 
PUFA use in patients with NAFLD, and while there does not 
seem to be any serious adverse effects, further trial based data 
are needed. 
3.3. Monounsaturated Fats 
Monounsaturated fats are found in avocadoes, olive oil and 
nuts and are considered preferable to saturated fats in those 
with metabolic syndrome [40) . A systematic review of trials in 
type 2 diabetics indicated that monounsaturated fats may 
improve dyslipidemia but did not improve insulin resistance 
[41]. a finding replicated in trials of healthy male volunteers 
[42] . However there are no trials of monounsaturated fats in 
NAFLD patients to inform recommendations, and the current 
breadth of data, while favorable, is limited to observational 
human and animal data [43]. 
3.4. Trans Fatty Acids 
Trans fatty acids are industrially produced fats that are formed 
when liquid vegetable oils are hydrogenated to produce a solid 
fat used for margarines and food manufacturing [44]. They are 
abundant in fast foods, baked and deep fried goods, crackers 
and margarine [45) and are estimated to account for 2-3% of 
dietary calories in the US [46). Dietary trans fats have been 
legislated to be removed from food supplies in the US, Denmark 
and Canada because of their role in promoting dyslipidemia, 
inflammation and cardiovascular disease. However, while 
high intake is widely considered harmful, data from studies 
on whether trans fats promote incidence of diabetes remain 
inconclusive [44). 
The potential role of trans fats in inciting NAFLD has been 
studied in animal models [47]. In proof of concept studies, mice 
fed a diet high in trans fats and high fructose com syrup for 
16 weeks developed hyperinsulinemia and severe hepatic 
necroinflammation [48); when trans fats were eliminated, 
steatohepatitis improved [49] . Animal models also suggest a 
role for HCC development with high intake of dietary trans fats 
and high fructose com syrup [50). Overall, data from human 
epidemiologic studies and animal models [51) support elimi-
nating trans fats from the human diet, and further ·data 
are unlikely to change this recommendation given that 
randomized trials are unethical. On this basis, patients with 
NAFLD should be advised to mm1m1ze consumption by 228 
checking nutritional labels to assess content, which is now 229 
mandatory in many countries. 230 
3.5. Saturated Fats 231 
Saturated fats derived predominantly from animal sources 232 
have also been implicated in the pathogenesis of NASH and 233 
may have additive effects on hepatic fat deposition when 234 
consumed in parallel with high cholesterol [52). There are little 235 
data on the effect of saturated fats in patients with NASH, 236 
although a meta-analysis of 8 randomized trials including 237 
13,614 patients evaluating replacement of saturated fats with 238 
PUFA in the general population found a 10% reduction in 239 
coronary events for every 5% of energy intake conferred by 240 
PUFA, with little evidence for study heterogeneity (53]. Genetic 241 
variations m!ly influence risk of high saturated fat intake, as 242 
variations in the PNPLA3 gene are associated with susceptibility 243 
to NAFLD (54), and the type of dietary fat may influence hepatic 244 
steatosis via upregulation of PNPLA3 expression in liver cells. In 245 
mice fed a traditional Western diet with saturated fat, the 246 
hepatic expression of PNPLA3 was 23 times higher than that 247 
seen with regular chow-diet fed mice, and fully reversed with 248 
fasting [55] . Other animal data also support upregulation of 249 
PNPLA3 expression with a high carbohydrate diet [56] . These 250 
data suggest that it may be reasonable to advise reduction of 251 
saturated fats in preference of monounsaturated fats , although 252 
controlled trials in NAFLD patients are desirable. 253 
3.6. Macronutrients: Carbohydrates Including High 254 
Fructose Com Syrup 255 
Excess consumption of carbohydrates, and in particular fruc- 256 
tose, should be discouraged in people with NAFLD. The 257 
metabolism of fructose differs from that of glucose as it is 258 
almost completely extracted by the liver [57] and does not 259 
stimulate normal satiety mechanisms as glucose does, thereby 260 
promoting overconsumption (58]. The association of dietary 261 
fructose and insulin resistance syndrome broadly in epidemic- 262 
logic studies has been reviewed elsewhere (59). Cross sectional 263 
data in 427 NAFLD patients suggest that daily fructose ingestion 264 
from sweetened beverages is associated with more advanced 265 
liver fibrosis at biopsy, although paradoxically, no association 266 
with hepatic steatosis was seen (60) . Other observational data 267 
assessing short term overfeeding with fructose or glucose in 268 
humans indicate that even a 1 week high fructose (daily 269 
consumption of 4 glfructose/kglday) or high glucose (daily 270 
consumption of 3 glglucose/kglday) diet may cause reduced 271 
hepatic insulin sensitivity and increased liver fat content as 212 
measured by MR-S [61]. A randomized trial of high sucrose 273 
intake (1 liter of sweetened cola per day) vs . water, milk or 274 
artificially sweetened soft drink in overweight subjects was 275 
associated with greater hepatic fat deposition (measured by 276 
MR-S), skeletal fat deposition and serum triglycerides in the 277 
cola group [62). Fructose consumption may also promote 278 
inflammation in NASH by inducing bacterial overgrowth in 279 
the small intestine which increases endotoxin levels in the 280 
portal vein [63). Of interest, a recent trial challenges the 281 
assumption that changes are due to fructose only. In this trial, 282 
32 overweight males were randomized to high (25% of daily 283 
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intake) fructose or glucose intake for 4 weeks in total, with 
a primary outcome of hepatic triacylglycerol content and 
secondary outcomes of hepatic and systemic insulin resistance, 
and found no difference between the two groups [64]. This 
question deserves more interrogation, but currently, it seems 
prudent to advise limiting excess refined carbohydrate con-
sumption particularly that sourced from soft drinks and fruit 
juices, in favor of water and non-sweetened beverages. 
3 .7. Probiotics 
Somewhat similar to omega-3, the marketing and use of 
probiotic agents has preceded firm scientific evidence to support 
their efficacy [65], and there are currently more than 30 Cochrane 
systematic reviews addressing effect of probiotics in wide 
ranging conditions such as eczema, irritable bowel syndrome, 
pneumonia, urinary tract infections and premature labor with 
variable results. Probiotics consist of bacteria (e.g. Laetobaci!lus) 
and/or yeast (e.g. Saccharomyces boulardiQ that are part of the 
normal intestinal flora, and although probiotics generally have 
been promoted to cure a wide range of ailments, the evidence 
suggests that the efficacy of individual probiotics is specific to the 
condition and cannot be generalized [65]. 
There has been increasing interest in whether people with 
NAFLD/NASH have a dysfunctional microbiome that may 
promote progression of NAFLD via a breakdown of the normal 
small intestinal barrier and translocation of bacteria into the 
systemic circulation [66], leading to systemic inflammation, 
increased cytokines and insulin resistance [67]. Small bowei 
bacterial overgrowth is more common in people with NAFLD 
[68] although the diagnostic test used to verify this is of 
limited accuracy. In a proof of concept study, a 6 month trial 
of Lactobacillus and Bifidobacterium supplementation in NASH 
patients resulted in significantly less intrahepatic triglyceride 
(measured by MR-S), although BM! and waist circumference 
were unchanged [69]. A further trial of supplementation with 
mixed Lactobacillus and Bifidobacterium species for 6 months 
us. placebo indicated a reduction in liver stiffness measured 
by transient elastography [70], and a meta-analysis of 4 
randomized trials (N = 134) suggested that probiotics can 
reduce insulin resistance [71]. Currently, there is insufficient 
evidence to recommend probiotics but given their good safety 
profile (considered safe in most people with the exception of 
immunocompromised patients where there is a small risk of 
fungemia), further trials with clinically relevant liver related 
outcomes, and testing various types, doses and duration of 
treatment, would be informative. 
3.8. Coffee 
Coffee and caffeine intake may be inversely associated with 
liver fibrosis in people with NAFLD, although the evidence base 
consists of observational, rather than trial based data. The 
putative beneficial effects of coffee and caffeine in liver disease 
have been comprehensively reviewed [72] and while the exact 
hepatoprotective effects have not been elucidated, possible 
mechanisms are coffee's antioxidant, anti-inflammatory, and 
antifibrotic effects [73]. In a prospective study, the coffee 
consumption of patients with NAFLD was recorded at baseline, 
and 147 patients were followed for 7 years. Those who drank 
more coffee (3+ cups per day) had a lower fibrosis score 340 
measured by a noninvasive fibrosis scoring system [74] . However 341 
the strength of these conclusions is tempered by the inherent 342 
methodological limitations including change in coffee consump- 343 
tion over time and limited diagnostic accuracy of non-invasive 344 
scoring systems. In a further cross sectional study of all-cause 345 
liver disease patients with liver biopsy at baseline and data on 346 
coffee consumption collected 3 times over a 6 month period, 347 
daily coffee consumption was associated with significantly lower 348 
odds ofliver fibrosis [75]. Similar results have been replicated in a 349 
NASH specific cohort [76]. Interestingly, the benefits of coffee 350 
may be specific to caffeinated coffee rather than decaffeinated 351 
coffee or tea, as some studies have shown a statistically 352 
significant relationship for fibrosis reduction for caffeinated 353 
coffee only, while other data have shown an independent benefit 354 
for coffee in reduction ofhepatocellular carcinoma after control- 355 
ling for tea intake [77]. The exact dose of caffeinated coffee that 35u 
may be beneficial cannot be determined by the above data, 357 
which needs to be addressed by good quality prospective studies, 358 
although a statistically significant benefit has generally occurred 359 
with higher intake (e.g. 2-3 cups of caffeinated coffee per day, 360 
approximately 300 mg caffeine) . Overall, current observational 361 
data support encouragement of regular caffeinated coffee intake 362 
in people with NAFLD who already consume coffee, and provide 363 
an attractive therapeutic avenue for further study. 364 
3.9. Nuts 365 
Nuts are known to be high in omega-3 polyunsaturated fatty 3uu 
acids, which have prompted speculation that they may be 367 
beneficial in NAFLD. In a cross sectional study of Korean adults 3u8 
with NAFLD, an inverse association was found between nut 3G9 
intake and risk of NAFLD [78]. Walnuts have been of particular 370 
interest given their high content of the omega-3 fatty acid, alpha- 371 
linolenic acid (ALA), and a high walnut intake is associated with 372 
lower prevalence of cardiovascular disease and type 2 diabetes in 373 
large epidemiological studies [79]. Further, supplementation with 374 
30 glday of walnuts in type 2 diabetics indicated reductions in LDL 375 
and increases in HDL (80]. These data are insufficient to support 37G 
recommendations on nut intake in NAFLD patients at present. 377 
3.10. Alcohol Consumption 378 
The evidence base for benefit of alcohol intake in NAFLD is 379 
conflicting and limited to observational data only. In a cross 380 
sectional study, increased intake was inversely associated 381 
with NAFLD, with an odds of having NAFLD of 0.80 for those 382 
who drink 1-3 days/week, and odds of0.52 for those who drink 383 
4-6 days per week [81]. although this association may be 384 
confounded by other lifestyle factors . Prospective data suggest 385 
that fibrosis worsens with heavy alcohol use, defined as heavy 38u 
episodic alcohol use at least once per month [82]. Contemporary 387 
clinical guidelines do not make conclusive recommendations 388 
on alcohol use and further prospective data is needed [83]. 389 
3.11. Dietary Interventions With Low Levels of Evidence 390 
Only: Protein, Choline, Resveratrol, and Fiber 391 
Currently, the evidence base for high protein diets or protein 392 
supplements in NAFLD is restricted to observational data 393 
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394 only. Experimental animal data suggest that dietary protein such 
395 as taurine may reduce hepatic inflammation in mice [84], and a 
396 small observational study of 11 women indicated that soy protein 
397 supplements reduced hepatic lipid content, but no clinical or 
398 patient important outcomes were studied [85]. Choline is an 
399 essential nutrient found in egg yolks and animal protein and it is 
400 speculated that choline deficiency can induce NAFLD. This 
401 predisposition is genetically mediated, yet human studies are 
402 needed to clarify whether supplementation may be therapeutic 
403 in NAFLD patients [86]. Resveratrol, a dietary antioxidant found 
404 in red wine appears to improve insulin sensitivity in humans 
405 [87], but whether it influences NAFLD has not been studied. 
406 Dietary fiber appears to have a positive effect on the microbiome 
407 [88] and reduces hepatic steatosis in rodent studies [89,90]. but 
408 human data are lacking. These interventions remain largely of 
409 theoretical interest until trials or well conducted prospective data 
410 are available. 
411 3.12. Potential Adverse Effects of Diets 
412 Little work has been done to comprehensively examine the 
413 adverse effects of dieting. Very low calorie diets (200--800 kcaVday) 
414 have been associated with electrolyte disturbance, hypotension 
415 and cholelithiasis [91,92], while low carbohydrate diets such as 
416 the Atkins diet are associated with ketosis and poor long term 
417 compliance [93]. Low carbohydrate diets may also have greater 
4 18 adverse effects on mood than a low fat diet [94]. Diets high in 
419 protein may improve satiety compared with low fat diets [95] 
420 but are linked with increased gastrointestinal disturbance such 
42 1 as constipation and halitosis [96]. Given the complexity of 
422 dieting effects on an individual level, and low adherence that 
423 , may ensue, clinical monitoring for adverse effects is needed. 
424 3.13. Summary of Dietary Recommendations (Table 1) 
T l 425 The m ajor dietary interventions in people with NAFLD and 
426 the level of supporting evidence (trial based us. systematic 
427 review/meta-analysis us. other) are summarized in Table 1. 
429 4. Exercise Interventions for NAFLD: Aerobic, 
430 Anaerobic or Both? 
43 1 Guidelines from specialty societies on exercise recommenda-
432 tions in NAFLD are variable. The American Association for the 
433 Study of Liver Diseases (AASLD) proposes that exercise can 
434 reduce hepatic steatosis in NAFLD, but does not make specific 
435 recommendations on the amount needed [11] . The European 
436 Association for the Study of the Liver (EASL) recommends that 
437 guidelines for diabetic patients be followed, namely 150 minutes 
438 of moderate intensity exercise per week, 75 minutes of vigorous 
439 intensity exercise per week and muscle strengthening exercises 
440 twice per week [121. This is in line with exercise recommenda-
44 1 tions for the general population (The American College of Sports 
442 Medicine recommends 3 to 5 sessions for 40 minutes for at least 
443 8 weeks for a significant improvement in V02 max) [97]. 
444 In epidemiological studies, levels of physical activity are 
445 correlated with the prevalence of metabolic syndrome [98-1001 
446 and this relationship is also seen in NAFLD. People with NAFLD 
447 are less active than the general population [101]. and the 
amount of activity is inversely associated with levels of 448 
intrahepatic fat independent of confounders such as age, sex, 449 
BM! and insulin resistance [102]. Krasnoff et al found that >80% 450 
of people with NAFLD did not meet recommended physical 45 1 
activity guidelines of 30 minutes of moderate exercise under- 452 
taken 3 or more times per week, and this result was true across 453 
the histological spectrum of NASH [103]. The largest biopsy- 454 
based study of people with NASH and physical activity levels 455 
suggests that the more severe the NASH, the lower the physical 456 
activity levels [104]. Clearly these data are not necessarily 457 
causal, and may even reflect inverse causality, but people who 458 
do more vigorous exercise appear to have a lower likelihood of 459 
advanced fibrosis [1041. 460 
While exercise recommendations form part of standard 461 
lifestyle modification advice to patients, whether to advise 462 
aerobic, anaerobic or combined modalities are uncertain, with 463 
benefits for both seen in prospective studies. In a cohort study of 464 
moderate intensity aerobic training, liver enzymes and insulin 465 
resistance improved after 3 months of weight training, inde- •166 
pendently of weight loss [105]. To further test this hypothesis, in 467 
a small trial by Bacchi, patients with type 2 diabetes were 468 
randomized to aerobic exercise (n = 13) or resistance training 469 
(n = 17) and a similar reduction in intrahepatic fat was observed 470 
in both groups [1061. However, the interpretation is somewhat 471 
limited by small sample size (n = 30) and Jack of a control group 472 
which precludes assumptions of improvement due to the 473 
intervention alone. A trial in 25 obese Japanese patients with •174 
NAFLD, randomized to 3 months of walking/jogging and caloric 4 75 
restiiction us. standard care, showed that exercise resulted in an •176 
improvement in steatosis [107]. Further to this, a meta-analysis 477 
of NAFLD patients participating in aerobic exercise programs 478 
showed that liver fat was significantly reduced, but substantial 479 
heterogeneity existed and the optimal exercise prescription is 480 
undetermined [108]. In addition, the important clinical question •181 
of whether reduction in liver fat translates to h ard endpoints 482 
such as reduced progression to chronic liver disease is unknown. 483 
Equally important to increasing exercise seems to be 484 
avoiding sedentary time [98]. Data from large population based 485 
studies suggest that time spent in sedentary activities is an 486 
independent predictor of insulin resistance syndromes, and 487 
consistently suggest that this is irrespective of moderate or even 488 
vigorous physical activity levels [98,109-112]. There are little data 489 
on risk of sedentary time specifically in people with NAFLD, but 490 
it seems reasonable to extrapolate these findings given the 491 
inextricable relationship of NAFLD to the metabolic syndrome, 492 
and recomrr.endations to limit sedentary time are sensible. •193 
4.1 . Special Considerations: Exercise in NAFLD Patients 494 
Who are Aged or Morbidly Obese 495 
Traditional aerobic exercise programs that include walking 496 
may be difficult to undertake in elderly, frail patients or those 497 
who are morbidly obese, despite the substantial advantages 498 
that exercise confers [11 3J. An alternative is resi stance 499 
training, as this is low impact and requires less energy 500 
expenditure and time compared with aerobic exercise [1141 . 501 
NAFLD patients undertake lower levels of habitual resistance 502 
exercise [115], and resistance training improves insulin 503 
resistance in NAFLD patients [116]. Resistance training may 504 
also improve autonomic dysfunction seen in NAFLD, thereby 505 
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Table 1- Nutritional interventions for people with NAFLD/NASH and available evidence from trials or systematic reviews. 
Intervention Description 
Mediterranean diet Diet high in monounsaturated fats and 
omega·3 PUFAs, vegetables, fruits and 
legumes with Jess meat and dairy intake 
Omega-3 PUFAs Omega-3 polyunsaturated fatty acids 
supplementation (500 mg to 3 g!day) 
Monounsaturated fats Fats found in olive oil, nuts and avocadoes 
Coffee 
Probiotics 
Nuts 
Olive oil 
Caffeinated coffee appears preferable to 
decaffeinated or tea, 2-3 cups per day 
(300 mg caffeine) 
Lactobacillus and BiJidobacterium species 
High in omega-3 PUFAs; walnuts 
most studied 
Dietary olive oil 
Level of evidence for people with metabolic Level of evidence for people with Comments 
syndrome or type 2 diabetes NAFLD/NASH 
Trial based data show benefits in dyslipidemia 
outcomes (16) 
Little evidence from Cochrane review for 
cardiovascular endpoints [20J 
Trial based dnta show benefit as secondary 
prophylaxis in recent infarct survivors (33) 
No clear benefit as primary prophylaxis (32J 
Systematic review based data show 
improve ment in dyslipidemia in 
type 2 diabetics (41J 
No Cochrane reviews in metabolic syndrome 
A trial of 30 g walnut supplementation improyes 
dyslipidemia (80] 
Cohort studies show reduced incidence of 
type 2 diabetes 
Trial based data for surrogate 
outcomes of hepatic steatosis 
and insulin resistance [22J 
Improvement in surrogate 
outcome of liver fat from single 
pediatric trial \36] and meta-analysis 
of adult trials (38( 
No trial based data 
No trial based data 
Trial based data sugges t less liver 
fat (69] 
Small trial suggests reduced liver 
stiffness IJOJ 
No trial based data 
No trial based data 
Reasonable evidence for improvement 
in surrogate outcomes, but not for hard 
clinical end points. f'urther trial based 
data needed 
Some evidence for surrogate outcomes 
but not for hard clinical end points. 
Minimal side effect profile 
Insufficient data 
Insufficient data, but reasonable to 
encourage ongoing intake in current 
coffee drinkers 
Insufficient data. Avoid in 
imrnunosuppressed patients 
Insufficient data 
Therapeutic s tudies in NAFLD are needed 
"' 
METABOLISM CL I NICAL AND EXPER I MENTAL XX (2015) XXX-XXX 7 
506 gradually enabling other forms of more vigorous exercise to 
507 be undertaken (117] . Where possible, tailored programs 
508 taking into account individual's co-morbidities are desirable 
509 to maximize training benefits (118]. 
5 10 4.2 . Summary for Exercise Recommendations 
5 11 Based on current data , it is reasonable to recommend exercise 
5 12 guidelines for diabetic patients as outlined above, unless 
5 13 further trial based evidence with liver related outcomes 
514 becomes available. Furthermore, advice on limiting sedentary 
515 time should also be given. Future research agendas should 
516 focus on exercise type, duration and frequency to better 
517 inform recommendations. 
519 5. Weight Loss for NAFLD: Do Patients Need to 
520 Lose Weight to Achieve Benefits? 
52 1 A practical question for clinicians is whether patients need to 
522 lose weight in order to improve liver specific outcomes. The 
523 benefits and harms of weight loss in NAFLD have been the 
524 subject of a Cochrane review which included 7 trials - 5 of diet 
525 and exercise and 2 of orlistat [119]. The authors concluded that 
526 as all trials had a high risk of selection bias due to unclear 
527 randomization, allocation techniques and loss to follow-up, it 
528 was not possible to make firm recommendations and better 
529 quality trials are needed. Individual trials show that aerobic 
530 exercise can reduce liver fat without weight loss (1 20]. and 
53 1 recent trial based evidence also suggests that weight loss 
532 correlates with histological improvement. A highly cited trial 
533 of weight loss in NASH revealed that a 7-10% loss of body 
534 weight was directly correlated with histological improve-
535 ment [121] . More recently, a cohort study of 293 patients 
536 prescribed a low fat diet and exercise program with a primary 
537 outcome of biopsy-proven resolution of NASH also found 
538 that weight loss correlated with histological improvement 
539 in a dose dependent fashion [122]. For those who lost 7-10% 
54 0 of body weight, 16/25 (64%) had resolution of steatohepatitis, 
54 1 whereas when weight loss was > 10%, 26/29 (90%) had 
542 resolution of steatohepatitis, and fibrosis regressed in. 45% 
543 of participants. Trials of weight loss medications such as 
54 4 orlistat in NASH have also indicated that histological 
545 improvement directly correlates with weight loss [123) . These 
5<16 good quality data suggest that where achievable, weight loss 
547 should be the primary target of any lifestyle modification 
548 program, although exercise alone may still provide benefits in 
549 reduction of liver fat. A note of caution however, that rapid 
550 weight loss by low carbohydrate ketogenic diets should be 
55 1 avoided, as they may worsen liver disease [124,125]. 
552 The benefits of weight loss for lean people, defined as those 
553 with a normal or only mildly elevated BM!, have not been 
554 studied, and there are scarce data on dietary differences. A 
555 retrospective cohort study that compared diets of 431 lean 
556 NAFLD patients with lean controls found no difference in 
557 dietary intake [126]. In this study, Hispanic ethnicity was a 
558 strong predictor of lean NAFLD, and this genetic predisposition 
559 is supported by data from an Asian cohort, who were found 
560 to develop insulin resistance at a lower BM! [127]. Given the 
56 1 likely central role of insulin resistance in lean NAFLD patients, 
s tudies assessing the benefits of dietary manipulation such as 562 
reduction in excess carbohydrate, with or without weight loss, 563 
would be instructive. 564 
6. Behavioral Strategies for NAFLD: 
Improving Adherence 
565 
567 
The manifold benefits of dietary and exercise regimes for people 568 
with NAFLD cannot be realized unless sustained behavioral 569 
change is achieved, using behavioral or cognitive behavioral 570 
therapies. Cognitive behavioral therapies focus on the interaction 571 
between cognition, behaviors and emotions, and propose that 572 
maladaptive behaviors can be rectified by focusing on cognitive 573 
processes behind them. This differs, at least theoretically, from 574 
behavioral therapies where cognition is not considered as 575 
important in maladaptive behaviors and is not targeted for 576 
intervention. However, the practical applications remain similar 577 
[128,129) . Psychological therapies may work because they directly 578 
target barriers to lifestyle modification that are not ad- 579 
dressed by traditional dietary counseling, such as boredom, 580 
stress, loss of motivation and maladaptive thought processes 58 1 
regarding weight loss [130,131]. Other barriers to lifestyle 582 
modification cited by NAFLD patients in particular include 583 
fatigue [13 2]. lack of confidence and fear of falling (133]. 584 
which are also amenable to behavioral therapy. Data from 585 
large trials in type 2 diabetes clearly illustrate the incremen- 586 
tal benefits of behavioral therapies such as individualized 587 
counseling and reinforcement measures (134]. and they are 588 
an integral part of obesity management programs, with clear 589 
evidence for their supporting role alongside diet and exercise 590 
recommendations [135]. In a cohort study ofNAFLD patients, 591 
cognitive behavioral therapy in addition to standard dietary 592 
prescription resulted in an additional weight loss and 593 
improved insulin resistance that was sustained at 2 years 594 
[1 36] and more frequent contact with therapists can result in 595 
significantly greater weight loss [105). Clinicians with no 596 
previous experience in CBT techniques should at least aim to use 597 
an 'engaging counseling style' and encourage self-empowerment 598 
techniques such as self-recording of food intake and physical 599 
activity (e.g. with a pedometer), and realistic goal setting 600 
[137]. and ideally, employ a multidisciplinary approach to 601 
patient care. fi02 
7. Conclusion 600 
In the absence of effective and acceptable pharmacological 605 
therapies, lifestyle modification with diet and exercise 606 
advice remains the cornerstone of management of NAFLD. 607 
Where available, and as outlined in this review, evidence 608 
based dietary recommendations from trials or systematic 609 
reviews of trials in NAFLD patients should be followed . 610 
Where evidence in NAFLD patients specifically is lacking, 611 
we believe ·chat it is reasonable to use good quality evidence 612 
from interventions in patients with similar pathophysiology 613 
such as metabolic syndrome or type 2 diabetes, given the 61 4 
close relationship between these disorders . For all patients, a 61 5 
multifaceted approach, using a multidisciplinary team is 61 6 
likely to achieve the best outcome. 617 
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